Mr. Bedford brings his expertise in business and finance to Zymeworks, after serving as Chairman of the Board of Directors of ActiveState Corporation, up to the time of its acquisition by Sophos UK. Additionally in the past, he has held senior positions at UBS Warburg, including the Frankfurt-based role as Head of German Equities. In this position he oversaw all sales and sales trading of equity products, and was responsible for the merger of UBS Germany's equity business with SBC Warburg. Prior to this he was with UBS' Securities division in Zurich, Tokyo, and London. Mr. Bedford holds a B.Sc. in Civil Engineering from King's College, London University.
Dr. Drakeman is a Venture Partner at Advent Venture Partners LLP, and holds a Ph.D. from Princeton University and a J.D. from Columbia University. Dr. Drakeman co-founded two international biotech companies focused on monoclonal antibody therapeutics; Medarex, Inc. and Genmab A/S. Under his leadership as CEO, Medarex raised over a billion dollars, formed alliances with multiple pharmaceutical companies, developed numerous therapeutic products, and spun-off Genmab, which completed Europe’s largest biotech IPO to date. In 2009, Medarex was subsequently acquired by Bristol-Myers Squibb for US$2.4 billion. During his 22 years in the biotechnology and pharmaceuticals industry, Dr. Drakeman has overseen the progress of over 30 innovative new medical products for cancer, infectious disease and inflammation from research concepts into clinical trials.
In 1972, Mr. Farris was one of the co-founding members and partners of the Ventures West Management group of venture capital funds, the largest venture capital pool in western Canada. Venture management experience includes finding, financing and developing high-technology startups and corporate turn-around opportunities. Since 1990, he has been President of Fractal Capital Corp., a private venture capital company financing high technology start-ups and resource service technology companies.
Mr. Farris holds a Bachelor of Arts (Economics & English) from the University of British Columbia, a Law Degree from the University of Pennsylvania Law School and an Honorary Doctor of Laws Degree from UBC.
Mr. Galbraith joined Ventures West in 2007 and leads the firm's biotech practice. Mr. Galbraith is a well-known and active member of the North American life sciences community with over 20 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. In 2006, Mr. Galbraith served as the Chairman and Interim CEO of AnorMED, a biopharmaceutical company focused on new therapeutic products in hematology, HIV and oncology, until its sale to Genzyme Corp. in a cash transaction worth almost $600 million. Previously, Mr. Galbraith spent 13 years in senior management with QLT Inc., a global biopharmaceutical company specializing in developing treatments for eye diseases and oncology, retiring in 2000 from his position as Executive VP and CFO. He currently serves as a Director of Alder Biopharmaceuticals, Aquinox Pharmaceuticals, Celator Pharmaceuticals, MacroGenics, NeurAxon and Presidio Pharmaceuticals.
Mr. Galbraith earned a Bachelor of Commerce (Honours) degree from the University of British Columbia and is a Chartered Accountant.
Mr. Noel Hall is a consultant to the life sciences industry with over 25 years of experience in the biotechnology sector. He was the Co-founder, President, and Director of Aspreva Pharmaceuticals, which was acquired by the Galenica Group in January 2008. Prior to Aspreva, Mr. Hall co-founded the life sciences practice of consulting firm Hill and Knowlton and served as Head of Global Strategic Planning for the firm’s worldwide pharmaceutical consulting practice. Mr. Hall was the Director of Corporate Affairs for the United Kingdom and Northern Europe for The Wellcome Foundation Ltd., which is now part of GlaxoSmithKline PLC. Additionally, Mr. Hall worked in market development with Abbott Laboratories Ltd. and was the regional sales manager with Leo Laboratories Ltd. Mr. Hall holds a B.Sc. degree in Medical Laboratory Science from London University, and currently serves on the board of directors of iCo Therapeutics Inc.
Mr. Ihnatowycz founded Acuity Funds Ltd. and Acuity Investment Management Inc. in 1990 to provide discretionary asset management for pension, foundation and private clients as well as mutual and pooled funds. A leader in sustainable investing, Acuity was the first Canadian advisor to the United Nations on the integration of environmental, social and governance factors within investment management. Acuity won many awards for investment performance over the years, and at the time of Acuity’s acquisition by AGF Management Limited in 2011, managed over $7.5 billion in client assets.
Mr. Ihnatowycz has served on the boards of numerous not-for-profit and professional organizations and private companies, is currently a member of the Board of Directors of the Investment Funds Institute of Canada and The Royal Conservatory of Music and is chair of the Royal Conservatory Council. Mr. Ihnatowycz’s degrees and professional designations include a B.Sc. (University of Toronto 1975), M.B.A. (University of Western Ontario, 1982), C.F.A. (1986), and Chartered Director (2005). He was honoured as a Fellow of the RCM in 2007 and presented with an Honorary Doctor of Philosophy from the Ukrainian Free University (Munich) in 2009.
Dr. Tehrani is one of Zymeworks' co-founders and currently serves as President and CEO of the company. He has been an integral part of many of the Company's corporate achievements including raising seed and angel financing and overseeing the Company's technical operations and patent filings. Dr. Tehrani holds both Bachelors and Masters of Science degrees in Biochemistry from the University of Massachusetts, and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. While completing his PhD degree he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002.
Dr. Tehrani has served on the MITACS Industrial Advisory Board, and BIOTECanada's Industrial and Environmental Committee. Currently, he is a member of the Board of Directors of LifeSciences British Columbia and the Student Biotechnology Network.
Dr. Tilley is a Partner at CTI Life Sciences Fund, L.P. Prior to joining CTI, Dr. Tilley was a Senior Vice President at Drug Royalty Corporation, a Bay Street private equity firm focused on biopharmaceutical investment. While at DRC she managed the due diligence and analysis group, and participated in transactions totaling over $200M. Before DRC, Dr. Tilley held faculty and research positions at the NYU School of Medicine and the Public Health Research Institute (PHRI), New York, and served on the PHRI Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the National Institutes of Health Small Business Innovation Research (SBIR) program.
Dr. Tilley holds a Ph.D. in biochemistry from the Johns Hopkins University School of Medicine and an MBA from the University of Toronto. In addition, she is a member of the Toronto Society of Financial Analysts, and since 2002 has served as a member of the University of Toronto School of Management (Rotman) Advancement Board. Dr. Tilley also sits as a board observer on the boards of Chlorion Pharma and NeurAxon.